Figure 6.
Soluble Aβ oligomer and APP levels are reduced in liraglutide-treated APP/PS1 mice. Oligomer β-amyloid levels and APP levels were measured by ELISA. Liraglutide significantly reduced both oligomer β-amyloid levels (A) (Student's t test, p = 0.0109) and brain APP levels (B) (Student's t test, p = 0.0272).